Carcinoma of Unknown Primary

Top drugs studied for this disease

All Approvals Safety alerts Label changes Trial results Research Guidance Withdrawals

CLINICAL_TRIALS withdrawal · 2015-05-27
Clinical Trial Update: Gemcitabine, Docetaxel, and Capecitabine in Treating Patients With Cancer of Unknown Primary Origin [Phase 2]
Phase 2 trial evaluating gemcitabine, docetaxel, and capecitabine for carcinoma of unknown primary has been withdrawn.